VistaSeqSM Hereditary Cancer Panel is a multi-gene test that detects inherited mutations in genes which have been associated with an increased risk of developing hereditary cancers.
Mutations in different genes can cause the same type of cancer; conversely, one gene may be associated with multiple hereditary cancers.
NCCN Guidelines® and The Society of Gynecologic Oncology (SGO) note that hereditary multi-gene panels may be an efficient and cost–effective approach to genetic cancer testing when used in appropriate clinical settings.1,2
VistaSeq Hereditary Cancer Panel provides an assessment of genetic mutations within a panel of 27 genes known to be associated with hereditary cancer syndromes.
Summary of Genes and Commonly Associated Cancers
See VistaSeq Physician Brochure PDF for references in table above. VistaSeq also available without the BRCA1/2 genes.
Broadening Your Patients’ Options
The VistaSeq Hereditary Cancer Panel is designed to provide information that can be used to determine if there is an increased cancer risk in patients with an associated personal or family history. It is specifically designed to detect inherited mutations and is not appropriate for the detection of other types of mutations in acquired cancers.
7-10 mL whole blood in a lavender-top (EDTA) tube
Client Services: Oncology/Pathology 800-710-1800
Specimen Services/Pickup: 866-875-2271
NCCN Guidelines® is a trademark owned by the National Comprehensive Cancer Network, Inc.
- Genetic/Familial High-Risk Assessment: Breast and Ovarian. NCCN Guidelines Version 1.2015. Available at: http://www.nccn.org/professionals/ physician_gls/pdf/genetics_screening.pdf. Accessed May 15, 2015.
- 2. SGO Clinical Practice Statement: Next Generation Cancer Gene Panels Versus Gene by Gene Testing March 2014. Available at: https://www.sgo.org/clinicalpractice/guidelines/next-generation-cancer-gene-panels-versus-gene-by-gene-testing. Accessed May 18, 2015.